Current state of the art, multimodality research and future visions for the treatment of patients with prostate cancer:
- PDF / 204,256 Bytes
- 7 Pages / 595.276 x 793.701 pts Page_size
- 75 Downloads / 135 Views
RESEARCH
Open Access
Current state of the art, multimodality research and future visions for the treatment of patients with prostate cancer: consensus results from “Challenges and Chances in Prostate Cancer Research Meeting 2013” Stephanie E Combs1*, Jürgen Debus5, Günter Feick2, Boris Hadaschik3, Markus Hohenfellner3, Roland Schüle4, Jens-Peter Zacharias2 and Malte Schwardt4
Abstract A brainstorming and consensus meeting organized by the German Cancer Aid focused on modern treatment of prostate cancer and promising innovative techniques and research areas. Besides optimization of screening algorithms, molecular-based stratification and individually tailored treatment regimens will be the future of multimodal prostate cancer management. Effective interdisciplinary structures, including biobanking and data collection mechanisms are the basis for such developments.
Introduction Treatment of patients with prostate cancer has improved over the last decades, based on the understanding of tumor biology, molecular characteristics of tumors, improvement in surgical techniques as well as innovations in radiation oncology. Today, treatment of prostate cancer is an interdisciplinary task involving several treating disciplines and in some situations competing treatment options. Every modality is associated with distinct riskbenefit profiles, and intensive patient counseling as well as clinical and imaging findings are the basis for treatment decisions. Decades ago treatment usually was limited to radical surgical resection of the prostate or simple conformal radiation therapy being associated with side effects, such as incontinence, bowel dysfunction and impotence, among others. Nowadays, improved anatomic nerve-sparing surgical approaches, development of robot-assisted surgery and intensity modulated radiation therapy have improved * Correspondence: [email protected] 1 Technische Universität München (TUM), Klinikum rechts der Isar, Department of Radiation Oncology, Ismaninger Straße 2, 81675 München, Germany Full list of author information is available at the end of the article
the risk-benefit ratio. For certain indications, large randomized studies have shown that adjuvant radiotherapy can increase progression-free and overall survival. In general, radiotherapy has become a valid treatment alternative in patients with prostate cancer, and with definitive treatments applied with high-end radiotherapy long-term curation can be achieved. As individualized treatments are emerging, evaluation of molecular markers in tumor tissue, epigenetic factors or other risk constellations become more relevant and are focus of several research strategies. Biobanking structures are essential to expand knowledge in this regard. In the future, this novel information may help stratify patients for certain treatment modalities, treatment intensification or prevent subgroups of patients from over-treatment. To bundle all these relevant data and innovative concepts, a consensus meeting in 2013 funded by the German Cancer Aid was held brin
Data Loading...
